2024-10-11 - Analysis Report
## Merck & Co. Inc. (MRK) Stock Analysis

**Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance Summary:**

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** MRK: 71.33%, VOO: 134.82%
* **Cumulative Return Difference:** -62.32%
* **Relative Divergence:** 22.37% (meaning MRK is currently at the 22.37% percentile of its historical performance difference compared to VOO).

**2. Recent Price Movement:**

* **Closing Price:** $110.27
* **5-Day Moving Average:** $109.47
* **20-Day Moving Average:** $114.01
* **60-Day Moving Average:** $116.34

**3. Technical Indicators:**

* **RSI:** 24.96 (below 30 suggests oversold conditions)
* **PPO:** -0.49 (negative value indicates a bearish trend)
* **Delta_Previous_Relative_Divergence:** -17.43 (suggests a short-term downward trend)
* **Expected Return:** 0.0% (maximum 5-year expected return exceeding S&P 500, VOO)

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

* **Latest Earnings:** 2024-08-05, EPS of $2.15, revenue of $16.11 billion. 
    * Earnings exceeded analysts' expectations.

**5. News & Recent Issues:**

* **Recent Market Outlook for MRK:** 
    * Some analysts remain optimistic about MRK's long-term prospects, citing its strong product portfolio and pipeline.
    * Concerns remain about the company's dependence on Keytruda, its blockbuster cancer drug. 
* **Analyst Opinions and Performance Highlights:** 
    * **FINBOLD:**  Several analysts have issued "buy" ratings on MRK, citing its strong financial position and growth potential. 
    * **TipRanks:** MRK has an average analyst price target of $126.63, suggesting potential upside.

**6. Comprehensive Analysis:**

MRK has underperformed the broader market (S&P 500) over the past period. However, recent earnings results were positive and exceeded expectations, indicating a potential rebound. Technical indicators suggest that the stock is currently oversold and may be poised for a short-term rebound, but the bearish trend and the low expected return raise concerns.

**7. Conclusion:**

MRK is a well-established pharmaceutical giant with a strong product portfolio and pipeline. However, its recent underperformance and dependence on Keytruda present challenges. While the stock may be undervalued and poised for a short-term rebound, investors should monitor its long-term growth potential and consider its overall risk profile before investing.
